Could an antidepressant be better at treating Covid-19 than Merck's new, expensive pill? Plus, lots of pushback from parents expected as vaccines are approved for younger kids. - podcast episode cover

Could an antidepressant be better at treating Covid-19 than Merck's new, expensive pill? Plus, lots of pushback from parents expected as vaccines are approved for younger kids.

Oct 27, 202119 minSeason 1Ep. 374
--:--
--:--
Listen in podcast apps:
Metacast
Spotify
Youtube
RSS

Episode description

New research shows that a widely available antidepressant could be even more effective than a new pill from Merck at treating Covid-19. And it's much less expensive.

Speaking of that pill, Merck will allow a nonprofit group to manufacture it for low and middle income countries. But it won't allow for a generic option.

The FDA is expected to give final approval to Pfizer's vaccine for 5 to 11 year old kids later this week. How much resistance will we see from parents?

Yet another thing made worse by the pandemic: Childhood obesity.

To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy

Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
Could an antidepressant be better at treating Covid-19 than Merck's new, expensive pill? Plus, lots of pushback from parents expected as vaccines are approved for younger kids. | The On Deadline Podcast - Listen or read transcript on Metacast